To the Editor:
The association between Parkinson disease (PD) and apolipoprotein E (APOE) gene has been the subject of several studies. We first reported the observation that e4 carriers had on average four years earlier age at onset than those without e4 [Zareparsi et al., 1997] . We had estimated that a minimum sample of 400 patients was needed to detect earlier age at onset of PD in e4 carriers. In a study of 521 unrelated Caucasian PD patients, we found that e3e4/e4e4 patients had significantly earlier onset than e3e3 patients [Zareparsi et al., 2002] . Inzelberg et al. [2002] have combined the samples from different studies and report that they do not detect a significant difference in onset among e4 carriers and those without e4.
One possible explanation is that the strength of the association between APOE and onset of PD may differ between samples collected at different sites. In our study, the difference in onset between e3e4/e4e4 versus e3e3 ranged from 2.2 to 8.5 years among patient samples collected in Oregon and Washington, respectively [Zareparsi et al., 2002] . Furthermore, the two samples displayed different trends for effect of e2 on PD onset [Zareparsi et al., 2002] . Thus, it may not be suitable to combine samples from different centers without performing tests of heterogeneity. In fact, in two of the studies, e4 carriers had slightly earlier onset [Inzelberg et al., 1998; Oliveri et al., 1999] . In addition, the combined sample is based on samples from different ethnic backgrounds. It is possible that the effect of APOE on PD onset differs between ethnic groups as mentioned by Inzelberg et al. Inzelberg et al. [2002] confirm our finding of earlier onset in patients with positive family history. They further suggest that earlier onset in e4 carriers may be due to family history and patients with parkin mutations. It should be noted that the earlier onset in e3e4/ e4e4 patients was significant even after adjusting for the effect of family history on onset of PD. We agree that parkin mutations are reported in patients with an age at onset of greater than 30 years [Lucking et al., 2000] . Our recent studies indicate that five of our subjects had parkin mutations. Two were excluded from analysis because their age at onset was less than 30 years. For the remaining three, the APOE genotype, family history, and age at onset were as follows: 1) non-familial, e2e3, onset 37 years; 2) non-familial, e3e3, onset 39 years; and 3) familial, e3e3, onset 37 years. Thus, contrary to Inzelberg et al.'s [2002] suggestion, our findings could not have been due to the inadvertent inclusion of parkin mutation carriers. Exclusion of parkin mutation carriers strengthens our data in favor of earlier onset in e3e4/e4e4 versus e3e3, and in familial versus nonfamilial PD.
